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Post-translational modifications play an important role in
regulating protein structure and function in health and
disease.[1] Ubiquitylation is one example for such a modifica-
tion wherein both the extent (poly- versus mono-ubiquityla-
tion) and the sequence position of this modification dictates
the function and fate of the ubiquitylated protein.[2–4] In the
ubiquitylation process, three distinct enzymes, known as the
E1–E3 system, collaborate to achieve a site-specific tagging of
the lysine residue(s) in target protein.[5] This condensation
step generates an isopeptide linkage between the e-NH2 of the
lysine residue and the activated C-terminal glycine of
ubiquitin (Ub). The overwhelming majority of the studies in
the field rely on the in vitro enzymatic reconstitution of this
complex posttranslational modification for the protein of
interest. This process is often challenged by the heterogeneity
of the modified protein, the isolation of the specific ligase
(E3), and obtaining reasonable quantities of the ubiquitylated
protein. In principle, adopting chemical and semisynthetic
strategies for the preparation of posttranslationally modified
protein could overcome these challenges and allow for site-
specific ubiquitylation of the modified protein in sufficient
quantities for biochemical and structural studies. With respect
to Ub, early efforts in these directions include the total
synthesis of Ub using stepwise solid-phase peptide synthesis[6]
(SPPS) and native chemical ligation (NCL),[7] semisynthesis
of Ub analogues with C-terminal electrophile,[8] and chemical
manipulation of the polyubiquitin chain.[9]
Recently, Muir and co-workers devised an elegant semi-
synthetic approach that allows site-specific peptide[10] and
protein mono-ubiquitylation.[11]This strategy relies on attach-
ing a photoremovable auxiliary[12] to a lysine residue to
mediate isopeptide formation with the Ub-a-thioester. This
concept was then applied to synthesize a homogeneous
ubiquitylated histone H2B, which was used for the assembly
of the nucleosome in vitro. This study paved the way to
unravel the effect of mono-ubiquitylation on the mechanism
of stimulation of the Dot1-catalyzed histone H3 methyla-
tion.[11] Despite the success in obtaining a purely modified
ubiquitylated histone H2B, the crucial step in the synthesis,
that is, the isopeptide formation mediated by the photo-
removable auxiliary, proceeded slowly, and required five days
for ubiquitylation and seven days for SUMOylation (small
ubiqutin-like modification) to achieve a reasonable conver-
sion to the mono-ubiquitylated product.[13] The slow ligation
rate was attributed to the involvement of the secondary amine
in the S-N acyl transfer, despite proceeding through a five-
membered ring transition state.[14] Indeed, in sugar- and side-
chain-assisted ligation, the rates are reasonable (6–48 h)
despite the reaction proceeding through 14–15-membered
ring intermediates for S-N acyl transfer. The involvement of a
primary amine in the acyl transfer step, along with to the
proximity effect, is a crucial factor.[15]
Inspired by NCL, the ligation method developed by Kent
and co-workers,[16] we reasoned that the formation of five-
membered-ring transition state involving the primary e-NH2
should have a major influence on the ligation rate. This
method would require the installation of a thiol group at the
lysine side-chain specifically on the d-carbon generating a
cysteine-like system (Scheme 1). With this in mind, we
devised a new thiol-modified lysine analogue, that is,
d-mercaptolysine, to allow a thiol capture step with the Ub-
a-thioester, followed by S-N acyl transfer, to form the
isopeptide linkage. Moreover, this modification should be
removable by applying the desulfurization reaction devel-
oped by Dawson and Yan[17] to furnish the unmodified lysine
(Scheme 1).
Initially, we focused on the synthesis of the d-mercapto-
lysine. We realized that the chiral center on the d-carbon
could be installed in its diastereomeric form, as it will be
removed after the desulfurization, which simplifies the syn-
thesis and purification steps. The synthesis of modified lysine
started from commercially available l-glutamic acid, which
was converted into aldehyde 1 in three steps according to a
previously reported procedure (Scheme 2).[18] Subsequently,
the Henry reaction was applied to 1 with nitromethane, in the
presence of TBAF as a base, to give a diastereomeric mixture
of nitro alcohol 2 in a 1:1 ratio (based on 1H NMR
spectroscopy; see the Supporting Information). The one-pot
acetylation, followed by elimination of the alcohol function-
ality on the nitro alcohol 2 using acetic anhydride and
4-dimethylaminopyridine, afforded the E/Z mixture of the
Michael acceptor 3 in 71% yield. To avoid any racemization
at the a carbon, the reaction of lithium tert-butylsulfide with
conjugated nitro olefin 3was performed at78 8C to furnish a
diasteromeric mixture of tert-butylmercapto nitro compound
4 in a ratio of 52:48 (see the Supporting Information). Next,
the reduction of nitro group to the amine using NaBH4 and
NiCl2<M.> 6H2O,
[19] followed by protection with allyloxy-
carbonyl chloride, afforded the alloc-protected tert-butyl
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mercaptolysine 5 in 69% yield (over two steps). To avoid any
racemization at the a carbon during the saponification step,
the two Boc protecting groups were removed by purging
hydrogen chloride gas through 5 in dry ethyl acetate, and the
resultant amine hydrochloride was masked as NH-Boc
derivative to give 6 in 96% yield (over two steps). This
compound was hydrolyzed using LiOH in THF/H2O at 0 8C to
afford the desired d-(R,S)-mercaptolysine 7 in a quantitative
yield.
To verify that the chiral integrity of the a carbon in
d-(R,S)-mercaptolysine was not affected during any step of
the synthesis, we carried out the following study. Two peptides
based on the sequence FKPSD (PheLysProSerAsp) were
prepared bearing the lysine residue in the l- and d- form,
generating F-l-LysPSD and F-d-LysPSD, which showed an
excellent separation on the reverse-phase HPLC. The same
sequence was then used wherein the lysine residue was
replaced with the d-(R,S)-mercaptolysine 7 and was subjected
to a desulfurization reaction to generate the FKPSD pep-
tide(s). HPLC analysis, under the same conditions that were
used to separate the above diastereoisomer peptides, showed
that only the F-l-LysPSD was observed, thus providing
evidence that the chiral integrity of the a-carbon in the
d-(R,S)-mercaptolysine 7 was completely retained (see the
Supporting Information).
With this amino acid at hand, we then turned our attention
to the synthesis of the target peptide bearing the d-mercap-
tolysine for site-specific ubiquitylation. For this purpose, we
chose the N-terminal segment of a-synuclein(1–17) as a
model peptide, driven by our interest to determine the effect
of post-translational modifications, such as ubiquitylation, on
a-synuclein aggregation and toxicity in Parkinsons disease
and related synucleinopathies.[20] Although four lysine resi-
dues, at residues 21, 23, 32, and 34 of the a-synuclein
N-terminal, were found to be liable to ubiquitylation in vitro,
a-syn ubiquitylation in vivo occurs at lysine 6, lysine 10, and
lysine 12.[20] The model peptide we selected
(MDVFMKGLSKAKEGVVA) contains the desired lysine
residues, from which lysine 6 was modified with d-mercapto-
lysine and synthesized using Boc-SPPS. Upon completion of
the synthesis, the alloc protecting group was removed using
[Pd(PPh3)4]/TIS (TIS= triisopropylsilane), followed by treat-
ment with trifluoroacetic acid/trifluoromethylsulfonic acid/
thioanisol/1,4-dithiothreitol (80:8:8:4) for cleavage from the
solid support and side-chain deprotection, to give the desired
peptide 8 in about 22% yield of isolated product (see the
Supporting Information). A recombinantly expressed HA-
tagged Ub(1-76)-a-thioester 9 (HAUb-SR; HA=hemaglut-
tinin) was prepared in 10 mg quantities by treating 50 mg
intein-fusion protein with mercaptoethanesulfonic acid as
previously described.[8,21]
With all the necessary building blocks at hand, we started
our ligation studies between peptide 8 and 9 (HAUb-SR).
Thus, HAUb-SR (2 mm) was treated with peptide 8 (2 equiv)
Scheme 1. Proposed mechanism for peptide ubiquitylation using
d-(R,S)-mercaptolysine.
Scheme 2. Synthesis of d-(R,S)-mercaptolysine for Boc-SPPS:
a) MeNO2, TBAF, 5 to 0 8C, 30 min., 97%; b) Ac2O, DMAP, ether,
0 8C to RT, 4 h, 71%; c) tBuSH, BuLi (1.6m), 10 to 78 0 8C,
45 min., 85%; d) 1) NaBH4, NiCl2·6H2O, THF/MeOH (1:1), 20 to
15 8C, 20 min., 2) AllocCl, TEA, THF, 0 8C to RT, 1 h, 69% for two
steps; e) 1) HClg, ethylacetate (dry), 20 8C, 1 h; 2) (Boc)2O, Et3N,
MeOH, 0 8C to RT, 2 h, 96% over two steps; f) LiOH, THF/H2O (3:2),
0 8C, 1 h, 95%. Boc= tert-butoxycarbonyl, TBAF= tetra-n-butylammo-
nium fluoride, DMAP=4-dimethylaminopyridine, Alloc=allyloxy
carbonyl, TEA= triethylamine.
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under NCL-like ligation conditions, that is, 6m Gn·HCl,
200 mm phosphate buffer, pH 7.5 in the presence of 2% v/v
thiophenol/benzylmercaptan.[22] The progress of the reaction
was followed by analytical HPLC and ESI mass spectrometry.
The ligation reaction proceeded rapidly, and a complete
conversion of the HAUb-SR 9was observed within 4 h to give
the desired ligation product 10 in 75% yield of isolated
product (Figure 1). Under similar conditions, the wild-type
peptide of a-synuclein(1–17) failed to show any traces of the
ligated product, which supports the proposed ligation mech-
anism shown in Scheme 1.
The ligation rate that was observed in this study, which is
very similar to the rate of Gly-Cys junction formation,[23] is
pleasantly surprising considering the differences in the
mercaptoamine structures compared to cysteine and isocys-
teine. The isocysteine case studied by Seitz andDose,[24] which
shows more similarity to our mercaptoamine structure, had a
ligation rate at pH 7.5 that is three times slower than for
cysteine. Moreover, the calculated pKa of the mercapto group
in d-mercaptolysine amide is pKa= 9.74, which is higher than
the calculated pKa values of isocysteine amide (pKa= 8.2) and
cysteine amide (pKa= 9.1).
[25] This fact, along with steric
factors of the secondary thiol, could influence the ligation
rate, considering that the rate-determining step in these
ligations is the thioesterification step. Nonetheless, we believe
that the absence of the carbonyl group in our mercaptoamine
structure, thus eliminating the inductive effect, combined with
the higher flexibility in our system, enhance the nucleophi-
licity of the thiolate and compensate for the higher pKa of the
mercapto functionality.
Following the ligation step, the ubiquitylated a-syn(1–17)
10 was treated with the metal-free desulfurization conditions
of Danishefsky and Wan[26] that were recently used to
desulfurize other residues after assisting ligation at a non-
cysteine junction.[27] Despite the presence of several methio-
nine residues, we observed a clean, rapid, and full conversion
of the starting material to the unmodified isopeptide ligation
product 11 (Figure 2). As determined by HPLC and ESI mass
spectrometry, the reaction was complete within 3–4 h, and a
mass decrease of 32 Da from the starting material was
observed, which is consistent with the loss of one sulfur
atom (Figure 2). The desulfurized product was isolated in
85% yield and was found to be a good substrate for ubiquitin
C-terminal hydrolase, UCH-L3, providing further evidence
on the structure integrity of the isopeptide linkage and the
folding of the tagged-Ub. In this experiment, the desulfurized
product was treated with UCH-L3, as previously reported, to
furnish both the hydrolyzed Ub and the a-syn(1–17) (see the
Supporting Information). In certain cases, the use of
d-mercaptolysine could provide additional advantages: the
desulfurization step could be preformed simultaneously by
desulfurizing other specific residues (such as b-mercaptophe-
nylalanine,[28] penicillamine,[27a] and cysteine[17]), which are
used to assist ligation at non-cysteine junctions as in the case
of the ubiquitylated histone H2B.[11] However, the presence of
other cysteine residues could hamper the use of our method,
which in principle could be overcome if temporary protection
of the native cysteine is performed.
To achieve the synthesis of full-length ubiquitylated
proteins, the synthetic strategy will often involve a second
ligation step along with ubiquitylation. In this case, protect-
ing-group manipulation of the mercaptolysine or the
N-terminal cysteine will be required to achieve site-specific
ubiquitylation and backbone ligation. To check the compat-
ibility of our method in systems that require multiple
ligations, we tested our strategy with model peptides 12
(Thz-a-syn(2-17); Thz= 1,3-thiazolidine-4-carboxyl) and 13
Figure 1. Peptide ubiquitylation: A) Analytical HPLC of the time-course
for the ligation reaction of model peptide 8 and HAUb-SR 9. Peak (a)
corresponds to peptide 8 with the observed mass of 1805 Da (calcd
1806 Da); (b), HAUb-SR 9, obs. 10215 Da (calcd 10216 Da); (c),
ligation product 10 (total protein), obs. 11878.2 Da (calcd
11878.3 Da); (d), benzylmercaptan thiol exchange intermediate, obs.
10197 Da (calcd 10198 Da). No HAUb-SR 9 starting material of was
detected after 30 min. B) Deconvoluted ESI mass spectrum (right) of
the ligation product 10 obtained from the unprocessed charge state
spectra (left).
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(LYRAG-SR). Model peptide 12 (see the Supporting Infor-
mation) was designed to include the d-mercaptolysine and
protected N-terminal cysteine residue (Scheme 3). Peptide 12
was first ubiquitylated with HAUb-SR 9 to furnish the
ubiquitylated product, which was then subjected, without
product isolation, to methoxylamine to unmask the
N-terminal cysteine, furnishing peptide 14 in 75% yield of
isolated product (Figure 3A).[7] Product 14 was ligated with
13 under NCL conditions to allow for backbone assembly,
affording the ligation product 15 (see the Supporting Infor-
mation). Applying the desulfurization reaction on 15 led to
the complete conversion of the cysteine residue to Ala, along
with the full removal of the thiol handle from the
d-mercaptolysine residue, to give the desulfurized product
16 in 78% yield of isolated product (Figure 3B). This model
study emphasizes that our strategy could, in principle, be used
in sequential ligation for the synthesis of ubiquitylated
proteins.
In summary, we have shown a highly efficient and
chemoselective method for ubiquitylation of peptides using
the d-mercaptolysine wherein the thiol functionality serves as
a temporary handle in assisting isopeptide formation. Follow-
ing the ligation step, the thiol moiety at the d carbon was
rapidly converted into the unmodified lysine using the
desulfurization reaction. Our strategy, in combination with
NCL and EPL, should facilitate the synthesis of homogenous
ubiquitylated proteins for biochemical and structural studies.
We believe that d-mercaptolysine could find other uses in
peptide and protein chemistry, such as in peptide cyclizations
and decorating protein surfaces.[29] We are currently working
to apply this approach to study the effect of ubiquitylation
and SUMOylation on the function of a wide range of proteins,
including a-Syn.
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